Sign in

    Adam S. Grossman

    President and Chief Executive Officer (CEO) at ADMA Biologics Inc
    Board
    Since October 2011
    Age
    47 years
    Education
    Earned a B.S. in Business Administration with a specialization in International Business and Marketing from American University.
    Tenure
    Became a director in 2007, served as President and Chief Operating Officer until October 2011, and has been President and Chief Executive Officer since then, with an additional role as Interim CFO since April 2024.

    Also at ADMA Biologics Inc

    KK
    Kaitlin Kestenberg
    Chief Operating Officer and Senior Vice President, Compliance

    About

    Adam S. Grossman is the President and Chief Executive Officer of ADMA, having joined the company as a director in 2007 and advancing through successive leadership roles. He served as President and Chief Operating Officer until his promotion to CEO in October 2011, and later assumed the Interim CFO role in April 2024.

    With over 25 years of experience in the blood and plasma industry, his career encompasses significant expertise in launching products, managing clinical trials, and executing business development transactions. His professional journey includes pivotal roles at National Hospital Specialties, GenesisBPS, MedImmune, and the American Red Cross.

    On a personal note, he is closely connected to ADMA through his family, being the son of Dr. Jerrold B. Grossman, a co-founder and Vice Chairman of the company. This background, coupled with a solid educational foundation from American University, has contributed to his comprehensive approach to leadership in the healthcare sector.

    $ADMA Performance Under Adam S. Grossman

    Past Roles

    OrganizationRoleDate RangeDetails
    ADMAInterim Chief Financial Officer Since April 2024 Held prior to becoming CEO
    ADMAPresident and Chief Operating Officer 2007 - October 2011 Held before becoming CEO
    GenesisBPSExecutive Vice President of National Hospital Specialties 1994 - 2011 Launched new products, built/managing national and international sales forces, managed clinical trials, and executed business development transactions
    MedImmune, Inc.Marketing Team Member (RSV and CMV immunoglobulins) N/A Worked on marketing teams for RSV and CMV immunoglobulins
    American Red CrossRole in Biomedical Services Division N/A Launched new products with the Biomedical Services division

    External Roles

    OrganizationRoleDate RangeDetails
    Plasma Protein Therapeutics Association Chair of the North America Board of Directors Since September 2023 N/A

    Fixed Compensation

    Data from  FY 2025
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary $925,000 Annual Approved base salary for 2025
    RSUs 252,022 RSUs Vest quarterly over 4 years Grant Date: February 19, 2025; awarded under the ADMA Biologics, Inc. 2022 Equity Compensation Plan
    Stock Options 376,744 shares at $16.07 per share Vest 25% on one-year anniversary; remaining 75% vest monthly over next 3 years, fully vested on February 19, 2029 Grant Date: February 19, 2025; reflects fair market value

    Performance Compensation

    Data from  FY 2025

    No information available on performance compensation for 2025